onkoserv

aktuelle literatur

09.10.2012

Preoperative Needle Biopsy Improves the Quality of Breast Cancer Surgery

Indikationen:
Mammakarzinom
Substanzen:
Tumor-Marker / Diagnostik
08.10.2012

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

Indikationen:
Ovarialkarzinom
Substanzen:
Carboplatin

Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer

Indikationen:
Mammakarzinom
Substanzen:
Trastuzumab

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

Indikationen:
Kolorektales Karzinom
Substanzen:
Oxaliplatin, 5-Fluorouracil, Dauerinfusion, Leucovorin, Bevacizumab, Cediranib
05.10.2012

Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27

Indikationen:
Mammakarzinom

Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study

Indikationen:
Mammakarzinom
Substanzen:
Carboplatin, Trastuzumab, Doxorubicin, liposomal

Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer

Indikationen:
Kopf- und Hals- Tumore
Substanzen:
Cisplatin, Pemetrexed
04.10.2012

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Indikationen:
Mammakarzinom
Substanzen:
Trastuzumab Emtansin (T-DM1)

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Indikationen:
Melanom
Substanzen:
Trametinib, Dabrafenib

Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database

Indikationen:
NHL
Substanzen:
Rituximab